DNA methylation signature (SAM40) identifies subgroups of the Luminal A breast cancer samples with distinct survival

Breast cancer patients with Luminal A disease generally have a good prognosis, but among this patient group are patients with good prognosis that are currently overtreated with adjuvant chemotherapy, and also patients that have a bad prognosis and should be given more aggressive treatment. There is...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Oncotarget
Asıl Yazarlar: Fleischer, Thomas, Klajic, Jovana, Aure, Miriam Ragle, Louhimo, Riku, Pladsen, Arne V., Ottestad, Lars, Touleimat, Nizar, Laakso, Marko, Halvorsen, Ann Rita, Alnæs, Grethe I. Grenaker, Riis, Margit L.H., Helland, Åslaug, Hautaniemi, Sampsa, Lønning, Per Eystein, Naume, Bjørn, Børresen-Dale, Anne-Lise, Tost, Jörg, Kristensen, Vessela N.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Impact Journals LLC 2016
Konular:
Research Paper
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC5352035/
https://ncbi.nlm.nih.gov/pubmed/27911866
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.13718
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller